Navigation Links
Another Record Year for BioTrinity
Date:4/26/2012

OXFORD, England, April 26, 2012 /PRNewswire/ --

Europe's premier biotech conference continues to grow and see increased international participation

OBN, the not-for-profit business network which provides comprehensive support for bioscience businesses in the Oxford and South-East England biocluster and beyond, today announced the results of the sixth annual BioTrinity Biopartnering and Investment Conference. Held from April 24 - 26 at Newbury Racecourse, UK, BioTrinity is now firmly established as the largest UK bioindustry event and one of the premier events in Europe. The conference has now been Europe's fastest growing early-stage investment and partnering event for four years running.

The 2012 conference welcomed 800 delegates from over 480 companies from 26 countries across Europe, Asia and North America. 70 investment firms that specialise in funding emerging biotechnology and life science companies participated as did 20 pharmaceutical companies including all of the global top 10. This year saw more than 1925 one-to-one partnering meetings scheduled. This was up from 1,700 in 2011, continuing a growth trend from 500 meetings in 2008.

The increasing international profile of BioTrinity was highlighted by the make-up of the panel discussions with more than 60% of participants being drawn from outside the UK and from the US, Europe and Asia.

"BioTrinity continues to go from strength to strength and is now clearly one of the "must attend" events for the sector not only in the UK but in Europe and increasingly internationally," said Jon Rees, CEO, OBN. "Not only have we continued to grow but we are attracting ever more senior participants from across the industry, from regulatory and government bodies and particularly from the pharma companies eager to partner with the highly innovative companies we showcase."

Denise Goode, Executive Business Development Director, AstraZeneca, said: "BioTrinity is one of the key events on the calendar for us. We are very active in seeking high quality partners and BioTrinity offers a highly efficient and effective way of doing that. In addition to the showcased companies, the partnering system works well and the high quality of the panels adds to overall breadth of the conference."

Dina Chaya, Venture Partner, NeoMed, said: "BioTrinity offers investors a great forum to meet exciting new companies and also to network with our peers. The invitation-only investor dinner is a unique event and the quality of the panels is second to none."

About OBN

OBN is a not-for-profit business network which provides comprehensive support for its member biotech and medtech companies in the Oxford and South-East England biocluster and the rest of the UK. Our activities can be summarised as networking, partnering, group purchasing, and fundraising advice. Through its delivery of Europe's fastest growing biopartnering and investment conference, BioTrinity, OBN generates more R&D-company-to-investor interactions than anyone else in Europe. OBN is sponsored by Shire, as Corporate Patron, and Corporate Sponsors MEPC, Manches LLP, James Cowper, George James, Interea International, SRG, FOCUS Insurance, World Courier and Citigate Dewe Rogerson as well as by its extensive membership of R&D companies and other companies across the entire life sciences industry ecosystem. OBN counts more than 200 companies amongst its membership, which is growing over 40% per year.

For further information on OBN and its activities, please visit: http://www.obn.org.uk

Contacts
OBN
Jon Rees, CEO
Tel: +44(0)845-5049722
jon.rees@obn.org.uk

Citigate Dewe Rogerson
Chris Gardner/Nina Enegren        
T: +44(0)20-7638-9571
chris.gardner@citigatedr.co.uk / nina.enegren@citigatedr.co.uk


'/>"/>
SOURCE OBN
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
2. Another Successful Year at Divine Skin
3. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
4. The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs
5. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
6. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
7. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
8. The first DFG research centers to be funded for another 4 years
9. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
10. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
11. Cephalon Reports Another Strong Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
(Date:2/23/2017)... , Feb. 23, 2017 Aviva Systems ... announced the acquisition of GenWay Biotech Incorporated, a ... service and product offering for both the research ... facilitate growth and enhance capabilities for both entities. GenWay,s ... ELISA assays will nicely complement ASB,s objective to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a ... Luncheon for all SPIE attendees and Park customers on Feb. 27, ... from the San Jose Convention Center. The luncheon will feature a talk on ...
(Date:2/22/2017)... Linda, Ca (PRWEB) , ... February 22, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, is ... will place on February 22 and 23, 2017. This premier, online-only conference focused ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
Breaking Biology News(10 mins):